Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
KER-065 is a modified Activin RII ligand trap that binds GDF8 and Activin A [5], which can be used as a standalone therapy or in combination with glucagon-like peptide-1 (GLP-1) receptor agonists
10.1002/hep.21006 233
(Published Ahead-of-Print November 2020
It increases the risk of: Type 2 diabetes Non-alcoholic fatty liver disease (NAFLD) Cardiovascular disease Simultaneously, the loss of estrogen accelerates sarcopenia , the loss of lean muscle mass, which further slows metabolism and reduces energy expenditure
US$ 27.19
US$ 23.92
.webp)
US$ 26.90
US$ 27.56
